Piramal Life Sciences Head Sees First Drug Launch In Two-Three Years
This article was originally published in PharmAsia News
CEO Ajay Piramal of Piramal Life Sciences, a recent spinoff of Piramal Healthcare, says the move enables the firm to become the first in India to launch globally its own discovered molecule. He said such a move would be a first because the "culture of research" has not existed in India. He said in an interview Piramal Life has six molecules in clinical trials, all in collaboration with global pharmaceuticals such as Eli Lilly, Merck and Pierre Fabre. The firm expects its first drug to reach the market as early as early as 2010. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.